XY Therapeutics

Fertility should not just be seen as a female issue - something being increasingly emphasized and recently highlighted by the Danish newspaper Debat. In the article, Marlene Stensballe, who is the CEO of Born, a large spermbank, gave her views of how the fertility field is changing. Article is in Danish.

We are proud and happy to share the research that has been published in Cell Reports Medicine - spearheaded by Martin Blomberg Jensen at Herlev og Gentofte Hospital. This research, which is the foundation of XY Therapeutics, shows that RANKL inhibition can boost sperm concentration in a subgroup of infertile men with high baseline AMH. The treatment increased germ cell proliferation in testis cultures and improved testicular health, highlighting potential for precision medicine in male infertility. We’re grateful for the recognition from the journal and the opportunity to contribute to the field of infertility. Martin Blomberg Jensen Nadia Krarup Knudsen Christine Hjorth Andreassen Rune Holt Li Juel Mortensen Lasse Nørregaard XY Therapeutics Herlev og Gentofte Hospital BioInnovation Institute Innovation Fund Denmark Novo Nordisk Foundation

We are thrilled to announce that XY Therapeutics has been awarded a Grand Solutions grant from Innovation Fund Denmark in collaboration with Centre for Diagnostics - DTU Health Technology and Herlev og Gentofte Hospital. This grant of 9.8M DKK will support the INFRANKL project that will revolutionize infertility treatment by developing innovative therapies for both male and female infertility. Martin Blomberg Jensen, Helene Larsen, Lasse Nørregaard, Jesper Freddie Sørensen, Sanne Schou Berger, Ilaria Mainero Rocca, Christine Hjorth Andreassen, Ida Marie Boi Jacobsen, Nadia N. Poulsen, Ireen Kooij, Anne Jørgensen, Lív Bech Árting, Nadia Krarup Knudsen, Gustav Wall-Gremstrup

New safety data out when using denosumab

Our collaborators at Herlev Hospital are opening a new translational lab and would like to invite you all to a symposium on "Bone and mineral homeostasis: from basic findings to clinical implications".   Date: Friday 23rd February 2024 Time: from 14:00-17:00 Where:        University Hospital of Copenhagen, Herlev auditorium and afterwards 54K1 official opening of Division of Translational endocrinology Address:      Borgmester Ib Juuls vej 1, 2730 Herlev Program  14:00                Welcome and presentation of Div.Translational Endocrin.                          Martin Blomberg Jensen, Head of research Endocrinology,  14:10                WNT signalling in the skeleton                           Prof. Roland Baron, Harvard University, US  14:40                Metabolic regulation of skeletal cell fate and function in physiology and disease                             Prof. Geert Carmeliet, Katholieke University Belgium  15:10                Targeting skeletal stem cells for treatment of age-related osteoporosis                             Prof. Moustapha Kassem, SDU, DK  15:40                Phosphate and bone signalling in the testis                             Post doc Ida Boisen Jacobsen, HGH  15:55                RANKL and male infertility – preclinical                             Post doc Christine Hjorth Andreassen HGH  16:10                RANKL and male infertility – clinical                             PhD student Rune Holt HGH 16:25                 Closure of symposium 16:30-17:30   Reception and official opening of the new Laboratory in Division of Translational Endocrinology 54K1 and 54O4   If you are interested, please send an email to elin.dahms.koenig@regionh.dk, to let them know that you will participate.